Eli Lilly and Company $LLY Stock Bought by Weaver Capital Management LLC

Weaver Capital Management LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 11.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,552 shares of the company’s stock after purchasing an additional 748 shares during the period. Eli Lilly and Company accounts for 1.7% of Weaver Capital Management LLC’s portfolio, making the stock its 15th biggest position. Weaver Capital Management LLC’s holdings in Eli Lilly and Company were worth $8,738,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Triasima Portfolio Management inc. grew its holdings in shares of Eli Lilly and Company by 3.3% during the third quarter. Triasima Portfolio Management inc. now owns 10,376 shares of the company’s stock valued at $12,006,000 after purchasing an additional 330 shares during the last quarter. Financial Harvest LLC raised its position in shares of Eli Lilly and Company by 5.4% during the 3rd quarter. Financial Harvest LLC now owns 253 shares of the company’s stock worth $293,000 after purchasing an additional 13 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Eli Lilly and Company by 56.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 784,936 shares of the company’s stock worth $908,234,000 after purchasing an additional 283,911 shares during the last quarter. Brindle & Bay Financial Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 42.8% in the 3rd quarter. Brindle & Bay Financial Advisors LLC now owns 317 shares of the company’s stock worth $366,000 after purchasing an additional 95 shares during the last quarter. Finally, Mystic Asset Management Inc. lifted its holdings in shares of Eli Lilly and Company by 0.6% in the 3rd quarter. Mystic Asset Management Inc. now owns 2,287 shares of the company’s stock worth $2,647,000 after purchasing an additional 13 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Bank of America upped their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Leerink Partners raised their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Wells Fargo & Company raised their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. UBS Group set a $1,376.00 price target on shares of Eli Lilly and Company in a report on Friday, August 7th. Finally, The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the stock a “buy” rating in a research report on Thursday, September 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: European backing for Foundayo: The European Medicines Agency’s advisory committee issued a positive recommendation for Foundayo (orforglipron), Lilly’s once-daily oral GLP-1 treatment for obesity and type 2 diabetes. Final approval from the European Commission is still required, but the decision supports Lilly’s strategy to expand beyond injectable drugs and could broaden access to the rapidly growing weight-loss market. Eli Lilly’s GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
• Positive Sentiment: Additional obesity drugs could extend growth: Analysts and market commentators highlighted Foundayo, investigational retatrutide and other newer medicines as potential drivers of Lilly’s next growth phase, reducing dependence on Zepbound. Retatrutide remains in development, so its commercial contribution depends on clinical results and future regulatory approval. Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly’s Next Leg Higher
• Positive Sentiment: Pipeline diversification is improving: New Omvoh analyses showed meaningful one-year corticosteroid-free disease control in ulcerative colitis and Crohn’s disease, including patients who had failed prior biologics. Lilly also announced oncology research collaborations, adding potential long-term pipeline value beyond its GLP-1 franchise. New Omvoh Composite Outcomes Data
• Neutral Sentiment: Valuation remains a risk: Lilly’s exceptional obesity-driven growth and strong recent performance have pushed investor expectations high. Articles questioned whether future cash-flow growth is sufficient to justify the stock’s premium valuation, increasing the possibility of volatility if results or guidance disappoint. Eli Lilly’s Growth Is Exceptional. Is Its Valuation Asking Too Much?
• Negative Sentiment: Large shareholder sale adds a technical overhang: The Lilly Foundation is selling approximately 300,000 shares valued near $347 million. Reports indicate the transaction is not tied to concerns about Lilly’s business outlook, but a sizable sale can still raise short-term supply and sentiment concerns. Eli Lilly’s Biggest Shareholder Is Selling $347 Million of Stock

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock worth $15,958,170 in the last three months. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded up $6.42 during trading hours on Friday, hitting $1,258.04. The stock had a trading volume of 2,411,755 shares, compared to its average volume of 2,408,952. The stock’s fifty day simple moving average is $1,180.08 and its 200 day simple moving average is $1,107.98. The firm has a market capitalization of $1.18 trillion, a price-to-earnings ratio of 42.22, a PEG ratio of 1.67 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business’s revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 33.56 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.